Analysis of treatment effectiveness and complications associated with MammoSite™ breast brachytherapy in patients treated at a single institution
- 46 Downloads
The objective of the study was to present treatment and follow-up data over a 5-year period for patients treated with MammoSite™ breast brachytherapy at our institution. Patient data was collected regarding the specific treatment and planning volumes, the complications occurring during and after treatment, and the overall outcome of each patient relating to tumor-free survival.
We performed a retrospective analysis of patients who presented with early stage breast cancer and received breast conserving surgery. These patients elected to receive accelerated partial breast irradiation (APBI) using the MammoSite™ catheter device. Patients were treated with 30.6–34.0 Gy in 3.4 Gy fractions twice daily with a minimum of 6 h between fractions utilizing either a spherical or an ellipsoidal catheter device.
From October 2005 to November 2010, 78 patients eligible for our retrospective analysis were treated with APBI using the MammoSite™ catheter device. The median follow-up time was 80 months. Of the patients in our study, there were a total of 10 recurrences. Five of these recurrences were local, two of the recurrences were local or new primaries that eventually developed into widespread metastatic disease, and three of the recurrences were widespread metastatic disease. Two were considered new primaries due to receptor status change in the new tumor.
This case series of 78 patients having greater than 24 months of follow-up from a single institution provides important data regarding failure analysis with MammoSite™ accelerated partial breast irradiation. Our results show a higher rate of metastatic recurrence in the group of patients with positive nodal disease.
KeywordsMammoSite Brachytherapy Breast cancer Postoperative radiation
Compliance of ethical standards
No funding support is associated with this study.
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human or animal subjects performed by any of the authors.
Statement of informed consent was not applicable since the manuscript does not contain any patient data.
- 5.Vicini F et al (2011) Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 79(3):808–817CrossRefPubMedGoogle Scholar
- 12.Correa, C. et al (2016) Accelerated partial breast irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat OncolGoogle Scholar
- 15.Yashar CM et al (2011) Initial clinical experience with the Strut-Adjusted Volume Implant (SAVI) breast brachytherapy device for accelerated partial-breast irradiation (APBI): first 100 patients with more than 1 year of follow-up. Int J Radiat Oncol Biol Phys 80(3):765–770CrossRefPubMedGoogle Scholar
- 20.Wolmark N et al. (2011) NSABP protocol B-39/RTOG protocol 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancerGoogle Scholar
- 22.Julian T et al (2011) Updated Early Toxicity Results with 3-D Conformal External Beam Therapy (CRT) from the NSABP B-39/RTOG 0413 Accelerated Partial Breast Irradiation (APBI) Trial. In: ASCO Annual Meeting. doi: 10.1200/jco.2011.29.15_suppl.1011
- 30.Sadeghi A et al (2006) Evaluation of the surface radiation dose and dose gradient in early stage breast cancer using high-dose-rate brachytherapy MammoSite applicator. Brachytherapy 5(4):230–234Google Scholar
- 32.Beitsch P et al (2010) Five-year outcome of patients classified in the "unsuitable" category using the American Society of Therapeutic Radiology and Oncology (ASTRO) Consensus Panel guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite® Registry trial. Ann Surg Oncol 17(Suppl 3):219–225CrossRefPubMedGoogle Scholar